Suggested Reading and Resources

Aurora S. Botulinum toxin type A for the treatment of migraine [review]. Expert Opin Pharmacother. 2006;7(8):1085-1095. View abstract

Baird MW, Vargus-Adams J. Outcome measures used in studies of botulinum toxin in childhood cerebral palsy: a systematic review [review]. J Child Neurol. 2010;25(6):721-727. View abstract

Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix-x, 1-111. View abstract

Botox [package insert]. Irvine, CA: Allergan Inc; 2010.

Brashear A, Gordon MF, Elovic E, et al; Botox Post-Stroke Spasticity Study Group. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347(6):395-400. View abstract

Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004;85(5):705-709. View abstract

Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Muscle Nerve Suppl. 1997;6:S208-S220. View abstract

Cardoso E, Rodrigues B, Lucena R, Reis de Oliveira I, Pedreira G, Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr. 2005;63(1):30-33. View abstract

Charles PD. Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses. Am J Health Syst Pharm. 2004;61(22 suppl 6):S11-S23. View abstract

Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. Am J Health Syst Pharm. 2006;63(2):145-152. View abstract

Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 2. Am J Health Syst Pharm. 2006;63(3):225-232. View abstract

Childers MK. The importance of electromyographic guidance and electrical stimulation for injection of botulinum toxin. Phys Med Rehabil Clin N Am. 2003;14(4):781-792. View abstract

Childers MK. Targeting the neuromuscular junction in skeletal muscles. Am J Phys Med Rehabil. 2004;83(10 suppl):S38-S44. View abstract

Childers MK, Childers MK, Brashear A, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85(7):1063-1069. View abstract

ClinicalTrials.gov. Dysport studies. Available at: http://clinicaltrials.gov/ct2/results?term=dysport. Accessed September 22, 2010.

ClinicalTrials.gov. Myobloc studies. Available at: http://clinicaltrials.gov/ct2/results?term=myobloc. Accessed September 22, 2010.

ClinicalTrials.gov. Xeomin studies. Available at: http://clinicaltrials.gov/ct2/results?term=xeomin. Accessed September 22, 2010.

Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407-415. View abstract

Craven BC, Morris AR. Modified Ashworth scale reliability for measurement of lower extremity spasticity among patients with SCI. Spinal Cord. 2010;48(3):207-213. View abstract

Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther. 2006;28(4):445-460. View abstract

Dajpratham P, Kuptniratsaikul V, Kovindha A, Kuptniratsaikul PS, Dejnuntarat K. Prevalence and management of poststroke spasticity in Thai stroke patients: a multicenter study.  J Med Assoc Thai. 2009;92(10):1354-1360. View abstract

Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity [review]. Drug Saf. 2004;27(11):799-818. View abstract

Davis EC, Barnes MP. Botulinum toxin and spasticity. J Neurol Neurosurg Psychiatry. 2000;69(2):143-147. View abstract

Denny-Brown D. The Cerebral Control of Movement. Liverpool, UK: University Press; 1966:124-143.

Deshpande S, Gormley ME Jr, Carey JR. Muscle fiber orientation in muscles commonly injected with botulinum toxin: an anatomical pilot study. Neurotox Res. 2006;9(2-3):115-120. View abstract

Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache. 2003;43(suppl 1):S16-S24. View abstract

Dysport [package insert]. Wrexham, UK: Ipsen Biopharm Ltd; 2009.

Elovic EP, Esquenazi A, Alter KE, Lin JL, Alfaro A, Kaelin DL. Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. PM R. 2009;1(9):842-851. View abstract

Esquenazi A. Botulinum neurotoxin in muscle overactivity. J Head Trauma Rehabil. 2005;20(6):563-567. View abstract

Esquenazi A. Evaluation and management of spastic gait in patients with traumatic brain injury. J Head Trauma Rehabil. 2004;19(2):109-118. View abstract

Esquenazi A. Improvements in healthcare and cost benefits associated with botulinum toxin treatment of spasticity and muscle overactivity. Eur J Neurol. 2006;13(suppl 4):27-34. View abstract

Esquenazi A, Mayer N. Botulinum toxin for the management of muscle overactivity and spasticity after stroke. Curr Atheroscler Rep. 2001;3(4):295-298. View abstract

Esquenazi A, Mayer NH. Instrumented assessment of muscle overactivity and spasticity with dynamic polyelectromyographic and motion analysis for treatment planning. Am J Phys Med Rehabil. 2004;83(10 suppl):S19-S29. View abstract

Esquenazi A, Mayer NH. Muscle overactivity in the upper motor neuron syndrome: functional and anatomical considerations [CD-ROM]. New York, NY: The Institute for Medical Studies; 2005.

Faist M, Mazevet D, Dietz V, Pierrot-Deseilligny E. A quantitative assessment of presynaptic inhibition of Ia afferents in spastics : differences in hemiplegics and paraplegics. Brain. 1994;117(Pt 6):1449-1455. View abstract

FDA requires boxed warning for all botulinum toxin products [news release]. Silver Spring, MD: US Food and Drug Administration; April 30, 2009. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm149574.htm. Updated January 4, 2010. Accessed September 22, 2010.

Fleuren JF, Voerman GE, Erren-Wolters CV, et al. Stop using the Ashworth scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry. 2010;81(1):46-52. View abstract

Frasson E, Priori A, Ruzzante B, Didonè G, Bertolasi L. Nerve stimulation boosts botulinum toxin action in spasticity. Mov Disord. 2005;20(5):624-629. View abstract

Ghotbi N, Ansari NN, Naghdi S, Hasson S, Jamshidpour B, Amiri S. Inter-rater reliability of the modified Ashworth scale in assessing lower limb muscle spasticity. Brain Inj. 2009;23(10):815-819. View abstract

Gioux M, Petit J. Effects of immobilizing the cat peroneus longus muscle on the activity of its own spindles. J Appl Physiol. 1993;75(6):2629-2635. View abstract

Gorassini MA, Knash ME, Harvey PJ, Bennett DJ, Yang JF. Role of motoneurons in the generation of muscle spasms after spinal cord injury. Brain. 2004;127(Pt 10):2247-2258. View abstract

Gordon MF, Brashear A, Elovic E, et al; BOTOX Poststroke Spasticity Study Group. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology. 2004;63(10):1971-1973. View abstract

Gracies JM. Pathophysiology of impairment in patients with spasticity and use of stretch as a treatment of spastic hypertonia. Phys Med Rehabil Clin N Am. 2001;12(4):747-768, vi. View abstract

Gracies JM. Pathophysiology of spastic paresis. I: paresis and soft tissue changes. Muscle Nerve. 2005;31(5):535-551. View abstract

Gracies JM. Pathophysiology of spastic paresis. II: emergence of muscle overactivity. Muscle Nerve. 2005;31(5):552-571. View abstract

Gracies JM. Physiological effects of botulinum toxin in spasticity. Mov Disord. 2004;19(suppl 8):S120-S128. View abstract

Gracies JM, Elovic E, McGuire J, Simpson D. Traditional pharmacologic treatments of spasticity. Part I: local treatments. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York, NY: WE MOVE; 2002:44-64.

Gracies JM, Nance P, Elovic E, McGuire J, Simpson D. Traditional pharmacologic treatments of spasticity. Part II: systemic treatments. In: Mayer NH, Simpson DM, eds. Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin. New York, NY: WE MOVE; 2002:65-93.

Gracies JM, Nance P, Elovic E, McGuire J, Simpson DM. Traditional pharmacological treatments for spasticity. Part II: general and regional treatments. Muscle Nerve Suppl. 1997;6:S92-S120. View abstract

Gracies JM, Simpson DM. Focal injection therapy. In: Hallett M, ed. Movement Disorders: Handbook of Clinical Neurophysiology. St Louis, MO: Elsevier Science BV; 2003:651-695.

Hesse S, Brandi-Hesse B, Bardeleben A, Werner C, Funk M. Botulinum toxin A treatment of adult upper and lower limb spasticity. Drugs Aging. 2001;18(4):255-262. View abstract

Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett. 1995;201(1):37-40. View abstract

Ivanhoe CB, Reistetter TA. Spasticity: the misunderstood part of the upper motor neuron syndrome. Am J Phys Med Rehabil. 2004;83(10 suppl):S3-S9. View abstract

Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27(5):234-244. View abstract

Kanovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32(5):259-265. View abstract

Keenan MA, Lee GA, Tuckman AS, Esquenazi A. Improving calf muscle strength in patients with spastic equinovarus deformity by transfer of long toe flexors to the Os calcis. J Head Trauma Rehabil. 1999;14(2):163-175. View abstract

Kim HS, Hwang JH, Jeong ST, et al. Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol. 2003;45(3):200-206. View abstract

Kinnett D. Botulinum toxin A injections in children: technique and dosing issues. Am J Phys Med Rehabil. 2004;83(10 suppl):S59-S64. View abstract

Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs. 2000;59(3):487-495. View abstract

Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type A neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics. 2001;108(5):1062-1071. View abstract

Koman LA, Mooney JF, Smith BP, Walker F, Leon JM; BOTOX Study Group. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop. 2000;20(1):108-115. View abstract

Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol. 2008;15(6):533-539. View abstract

Lynn AK, Turner M, Chambers HG. Surgical management of spasticity in persons with cerebral palsy [review]. PM R. 2009;1(9):834-838. View abstract

Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and Botox in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord. 2005;20(8):937-944. View abstract

Marque P, Simonetta-Moreau M, Maupas E, Roques CF. Facilitation of transmission in heteronymous group II pathways in spastic hemiplegic patients. J Neurol Neurosurg Psychiatry. 2001;70(1):36-42. View abstract

Mayer NH. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion [review]. Muscle Nerve Suppl. 1997;6:S1-S13. View abstract

Mayer NH, Esquenazi A. Muscle overactivity and movement dysfunction in the upper motoneuron syndrome. Phys Med Rehabil Clin N Am. 2003;14(4):855-883, vii-viii. View abstract

Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve Suppl. 1997;6:S21-S35. View abstract

McCrea PH, Eng JJ, Willms R. Phenol reduces hypertonia and enhances strength: a longitudinal case study. Neurorehabil Neural Repair. 2004;18(2):112-116. View abstract

Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20(5):592-597. View abstract

Mohammadi B, Balouch SA, Dengler R, Kollewe K. Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients. Neurol Res. 2010;32(3):309-313. View abstract

Morita H, Crone C, Christenhuis D, Petersen NT, Nielsen JB. Modulation of presynaptic inhibition and disynaptic reciprocal Ia inhibition during voluntary movement in spasticity. Brain. 2001;124(Pt 4):826-837. View abstract

Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today [review]. BMJ. 2000;320(7228):161-165. View abstract

Myobloc [package insert]. South San Francisco, CA: Solstice Neurosciences LLC; 2009.

Nordmark E, Josenby AL, Lagergren J, Andersson G, Strömblad LG, Westbom L. Long-term outcomes five years after selective dorsal rhizotomy. BMC Pediatr. 2008;8:54. View abstract

O’Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve Suppl. 1997;6:S176-S180. View abstract

O’Brien CF. Treatment of spasticity with botulinum toxin. Clin J Pain. 2002;18(6 suppl):S182-S190. View abstract

O’Dwyer NJ, Ada L, Neilson PD. Spasticity and muscle contracture following stroke. Brain. 1996;119(Pt 5):1737-1749. View abstract

Pathak MS, Nguyen HT, Graham HK, Moore AP. Management of spasticity in adults: practical application of botulinum toxin. Eur J Neurol. 2006;13(suppl 1):42-50. View abstract

Pierrot-Deseilligny E, Bergego C, Katz R. Reversal in cutaneous of Ib pathways during human voluntary reversal in cutaneous of contraction. Brain Res. 1982;233(2):400-403. View abstract

Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord. 2004;19(suppl 8):S129-S136. View abstract

Satkunam LE. Rehabilitation medicine: 3. Management of adult spasticity. CMAJ. 2003;169(11):1173-1179. View abstract

Sheean G. The pathophysiology of spasticity. Eur J Neurol. 2002;9(suppl 1):3-9. View abstract

Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46(5):1306-1310. View abstract

Slawek J, Bogucki A, Reclawowicz D. Botulinum toxin type A for upper limb spasticity following stroke: an open-label study with individualised, flexible injection regimens. Neurol Sci. 2005;26(1):32-39. View abstract

Sommerfeld DK, Eek EU, Svensson AK, Holmqvist LW, von Arbin MH. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004;35(1):134-139. View abstract

Suputtitada A, Suwanwela NC. The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil. 2005;27(4):176-184. View abstract

Synder M, Kumar SJ, Stecyk MD. Split tibialis posterior tendon transfer and tendo-Achillis lengthening for spastic equinovarus feet. J Pediatr Orthop. 1993;13(1):20-23. View abstract

Tilton AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol. 2003;18(suppl 1):S50-S66. View abstract

Verheyden J, Blitzer A, Brin MF. Other noncosmetic uses of BOTOX. Semin Cutan Med Surg. 2001;20(2):121-126. View abstract

Vitek JL, Giroux M. Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol. 2000;47(4 suppl 1):S131-S140. View abstract

Wang HC, Hsieh LF, Chi WC, Lou SM. Effect of intramuscular botulinum toxin injection on upper limb spasticity in stroke patients. Am J Phys Med Rehabil. 2002;81(4):272-278. View abstract

Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16(5):515-522. View abstract

WE MOVE. Resource library: movement disorders. Available at: http://www.mdvu.org/library/disease/spasticity/spa_mtp.html. Accessed June 18, 2007.

WE MOVE. Spasticity. Available at: http://wemove.org/spa/spa_epi.html. Accessed September 22, 2010.

Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers’ product summaries. J Clin Pharm Ther. 2007;32(4):387-402. View abstract

Wissel J, Müller J, Dressnandt J, et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage. 2000;20(1):44-49. View abstract

Xeomin [package insert]. Dessau-Rosslau, Germany: Merz Pharmaceuticals LLC; 2010.

Yablon SA. Botulinum neurotoxin intramuscular chemodenervation: role in the management of spastic hypertonia and related motor disorders. Phys Med Rehabil Clin N Am. 2001;12(4):833-874, vii-viii. View abstract

Yablon SA, Agana BT, Ivanhoe CB, Boake C. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: an open-labeled trial. Neurology. 1996;47(4):939-944. View abstract

Websites

Neurotoxin Institute. http://neurotoxininstitute.com/

WE MOVE. http://wemove.org/

<< back


Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower or Dannemiller and CogniMed Inc.
See individual activity for CME and sponsorship information.

This program is supported by an independent educational grant provided by Allergan, Inc.

© 2013 CogniMed Inc. All rights reserved.